Definium Therapeutics (DFTX) Profit After Tax (2021 - 2026)
Definium Therapeutics (DFTX) posted quarterly Profit After Tax of -$77.4 million for Q1 2026, down 231.09% year-over-year from $59.0 million in Q1 2025, and down 52.83% quarter-over-quarter from -$50.6 million in Q4 2025.
Definium Therapeutics (DFTX) Profit After Tax (2021 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Profit After Tax for 6 consecutive years, with -$77.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 231.09% year-over-year to -$77.4 million; the TTM figure through Mar 2026 stood at -$237.8 million (down 208.13% YoY), while the FY2025 annual figure was -$183.8 million, down 69.86% from the prior year.
- Profit After Tax retreated to -$77.4 million in Q1 2026 per DFTX's latest filing, from -$50.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$4.9 million in Q4 2022 and bottomed at -$77.4 million in Q1 2026.
- Historically, Profit After Tax has averaged -$30.7 million across 5 years, with a median of -$24.3 million in 2023.
- Annual changes were most pronounced in 2024 — Profit After Tax jumped 80.08% — and 2025, when it slumped 629.71%.
- Definium Therapeutics' Profit After Tax stood at -$4.9 million in 2022, then sank by 395.57% to -$24.3 million in 2023, then plunged by 41.02% to -$34.3 million in 2024, then plunged by 47.73% to -$50.6 million in 2025, then tumbled by 52.83% to -$77.4 million in 2026.
- Business Quant data shows DFTX's Profit After Tax at -$77.4 million in Q1 2026, -$50.6 million in Q4 2025, and -$67.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | -159.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -159.39 Mn |
| Mar 31, 2026 | -77.36 Mn |
| Dec 31, 2025 | -50.62 Mn |
| Sep 30, 2025 | -67.07 Mn |
| Jun 30, 2025 | -42.74 Mn |
| Mar 31, 2025 | -23.37 Mn |
| Dec 31, 2024 | -34.27 Mn |
| Sep 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | -5.86 Mn |
| Mar 31, 2024 | -53.91 Mn |
| Dec 31, 2023 | -24.30 Mn |
| Sep 30, 2023 | -17.51 Mn |
| Jun 30, 2023 | -29.41 Mn |
| Mar 31, 2023 | -24.80 Mn |
| Dec 31, 2022 | -4.90 Mn |
| Sep 30, 2022 | -16.49 Mn |
| Jun 30, 2022 | -16.96 Mn |
| Mar 31, 2022 | -18.45 Mn |
| Dec 31, 2021 | -16.45 Mn |
| Sep 30, 2021 | -17.58 Mn |